Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . HHM A HUA MEDICINE 華 領 醫藥 ( Incorporated in the Cayman Islands with limited liability ) ( Stock code : 2552 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30 , 2021 BUSINESS AND FINANCIAL HIGHLIGHTS In March 2021 , we submitted a NDA for dorzagliatin for the treatment of Type 2 diabetes to the NMPA , and we received notification from the NMPA that our NDA was accepted in April 2021 . We presented data from our 52 - week SEED and DAWN phase 3 registration trials , as well as phase 1 trial HMM0112 of dorzagliatin in combination with SGLT - 2 at the 2021 American Diabetes Association's Scientific Sessions demonstrating glucose control benefit using the combination . We presented additional data from our phase 1 trial HMM0111 of dorzagliatin in combination with DPP - 4 at the 2021 American Diabetes Association's Scientific Sessions , demonstrating that dorzagliatin regulates GLP - 1 secretion and providing additional benefit in glucose control in T2D patients in USA . In anticipation of dorzagliatin commercialization , subject to approval of its NDA , in addition to its CMO partnerships , Hua Medicine has also established Hua Medicine drug manufacture company at Shanghai Lingang Special Area for ensuring adequate dorzagliatin commercial supply . Cash position was approximately RMB846.9 million as of June 30 , 2021 . Total expenditures incurred by the Company for the six months ended June 30 , 2021 was approximately RMB165.1 million , of which approximately RMB98.0 million was attributable to research and development expenses . Research and development expenses decreased by approximately RMB14.3 million or approximately 12.7 % to approximately RMB98.0 million for the six months ended June 30 , 2021 , compared with the six months ended June 30 , 2020 . Loss before tax decreased by approximately RMB8.2 million or approximately 4.7 % to approximately RMB165.3 million for the six months ended June 30 , 2021 , compared with the six months ended June 30 , 2020 . Loss and other comprehensive expense for the period decreased by approximately RMB8.4 million or approximately 4.8 % to approximately RMB165.3 million for the six months ended June 30 , 2021 , compared with the six months ended June 30 , 2020 . 1